Evoke spinal cord stimulator overview The evoke spinal cord stimulator (SCS) is a rechargeable, implantable, closed loop stimulator for chronic pain management. The system is made up of an implantable closed loop stimulator (an external stimulator is used during an initial trial period), 1 or 2 leads connecting the stimulator to the spinal cord, a remote control for manually changing stimulation and a charging kit. The evoke stimulator (external or implantable) is programmed to deliver therapeutic SCS utilising feedback control by the Evoke Clinical interface and Evoke Clinical system Transceiver. The Evoke system utilises feedback control by recording activation of neural tissue and automatically adjusting stimulation to ensure it remains within the therapeutic range. The Evoke system is intended to replace conventional SCS for adults with chronic, intractable pain. The company claims the device offers patients improved pain relief and quality of life. The company also claim the technology has the potential to reduce costs related to opioid medication and the number of hospital visits.
Topic is paused whilst further topic intelligence is gathered
- Status:
- Suspended
- Decision:
- Selected
- Process:
- MTG
- ID number:
- 567
Project Team
- Project lead
- Rebecca Brookfield
Email enquiries
If you have any queries please email [email protected]
Stakeholders
- External assessment group
- KiTEC
- Manufacturers
- Saluda Medical
- Others
- Association of British Healthcare Industries (ABHI)
- Association of Healthcare Technology Providers for Imaging, Radiotherapy and Care (AXrEM)
- Boston Scientific
- Department of Health and Social Care
- Devices for Dignity
- Greater Manchester Health & Social Care Partnership
- Healthcare Improvement Scotland
- HealthTech Alliance
- Johnson & Johnson Medical Ltd
- Medical Technology Group
- Medicines and Healthcare Products Regulatory Agency
- University of Manchester Wounds Research Group
- NHS England
- The British In Vitro Diagnostics Association (BIVDA)
- NHS Digital
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 March 2023 | Suspended. Topic is paused whilst further topic intelligence is gathered |
For further information on our processes and methods, please see our CHTE processes and methods manual